Exploring new treatment combinations for triple-negative breast cancer
Investigating Rational Combination Therapies for Triple-Negative Breast Cancer
This study is looking for new treatment options for people with triple-negative breast cancer by testing combinations of therapies that can specifically target and kill cancer cells without harming healthy ones.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11005726 on NIH RePORTER |
What this research studies
This research focuses on triple-negative breast cancer (TNBC), a type of breast cancer that does not respond to common hormonal therapies. The study aims to identify effective combination therapies that target specific pathways involved in tumor growth, particularly those related to the MYC oncogene. By using a synthetic lethal screening approach, researchers are looking for druggable targets that can selectively kill cancer cells while sparing normal cells. This could lead to new treatment options for patients who currently have limited choices.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have not responded to standard treatments.
Not a fit: Patients with other types of breast cancer or those who have already received all available treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new targeted therapies that improve survival rates for patients with triple-negative breast cancer.
How similar studies have performed: Previous research has shown promise in targeting MYC-driven pathways in cancer, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Mendillo, Marc — Northwestern University at Chicago
- Study coordinator: Mendillo, Marc
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.